News for ARPO Stock

Aerpio Reports Second Quarter 2021 Financial Results and Provides Business Update Aerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting Aerpio Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting Aerpio Reports First Quarter 2021 Financial Results and Provides Business Update Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement Aerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical’s Razuprotafib in I-SPY COVID Trial Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update Aerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10 Aerpio Hosting Key Opinion Leader Call on New Therapeutic Agents for COVID-19 Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19 Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial Aerpio Reports Second Quarter 2020 Financial Results and Provides Business Update Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12 Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma Aerpio Reports First Quarter 2020 Financial Results and Provides Business Update Aerpio Announces Change to Virtual Format for its 2020 Annual Meeting of Stockholders due to COVID-19 Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924)